Abstract
The present invention is related to use of nanoparticle containing tyrosin kinase inhibitor for the manufacture of pharmaceutical composition for ameliorating liver fibrosis. The present invention utilizes copolymers of polyethylene glycol and poly (D, L-lactide-co-glycolide) to form nanoparticle containing tyrosin kinase inhibitor, such as Sorafenib. The use of nanoparticle is non-toxic and can increase the stability and decrease the release of drug in blood circulation. The pharmaceutical composition is an injectable composition. The nanoparticle containing tyrosin kinase inhibitor of the present invention can effectively ameliorate liver fibrosis including decreasing extracellular matrix accumulation, suppressing hepatic stellate cell activity, shrinking of abnormal blood vessel, and lowering microvascular density in fibrotic liver; hence, is suitable for clinical application for the treatment of liver fibrosis.